Skip to content
OpenCapital
Get started

Boston Scientific BSX Interventional Oncology & Embolization — Net Sales

Other product segments

Interventional Cardiology & Vascular Therapies
$4.64B—
Electrophysiology
$905M+24.0%
Endoscopy
$736M+9.4%
Urology
$646M+2.1%
Cardiac Rhythm Management
$578M0.0%
Watchman
$506M+19.1%
Neuromodulation
$318M+17.3%

Similar metrics at other companies

Penumbra logo
PENEmbolization and Other — Revenue
$113.94M+20.2%
Penumbra logo
PENEmbolization and Access — Revenue
$120.84M+23.8%
Penumbra logo
PENNeuro — Revenue
$171.41M+38.9%
Penumbra logo
PENThrombectomy — Revenue
$253.92M+12.1%
Baxter International logo
BAXSurgical Solutions — Net Sales
$77M+11.6%
Penumbra logo
PENVascular — Revenue
$99.54M+10.2%

Other financials

Income statement

See full
Revenue$5.2B+11.6%
Gross profit$3.6B+12.6%
Operating income$1.1B+19.5%
Net income$1.3B+99.3%
EPS (diluted)$0.90+100%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$67.32B-37.5%
P/E18.9×-34.3×
P/S3.3×-2.9×

Profitability

See full
Gross margin69.2%+0.5pp
Operating margin18.4%+2.2pp
Net margin17.3%+5.7pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity0×-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Boston Scientific's interventional oncology & embolization — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Boston Scientific's interventional oncology & embolization — net sales?
Boston Scientific (BSX) reported interventional oncology & embolization — net sales of $268M in Q1 2026.
How has Boston Scientific's interventional oncology & embolization — net sales changed year-over-year?
Boston Scientific's interventional oncology & embolization — net sales increased by 17.5% year-over-year, from $228M to $268M.
What does interventional oncology & embolization — net sales mean?
Total revenue generated from the sale of medical devices used in interventional oncology and embolization procedures.
How do you interpret interventional oncology & embolization — net sales?
An increase indicates growing market adoption of the company's oncology-focused medical devices and successful expansion of its interventional product portfolio. A decrease may signal increased competition, pricing pressure, or a slowdown in the adoption of specific minimally invasive oncology treatments.
How does interventional oncology & embolization — net sales compare across companies?
Comparable to specialized oncology or interventional radiology product line revenues reported by diversified medical device manufacturers or specialized medtech firms.